Open AccessNon-prostate uptake on 18F-PSMA-1007 PET/CT: a case of myeloma
Author(s) -
Sowmya Veerasuri,
Stewart Redman,
Richard Graham,
Chris Meehan,
David Little
Publication year - 2021
Publication title -
bjr case reports
Language(s) - English
Resource type - Journals
ISSN - 2055-7159
DOI - 10.1259/bjrcr.20200102
Subject(s) - prostate cancer , medicine , prostate , glutamate carboxypeptidase ii , nuclear medicine , positron emission tomography , pancreas , multiple myeloma , pathology , cancer
Prostate-specific membrane antigen (PSMA), a glycoprotein that is highly expressed in prostate cancer, has been used as a target for molecular radiotherapy as well as imaging. Over the last couple of years, 18 F-PSMA gained popularity due to its longer half-life (110 min) compared to gallium 68 Ga-PSMA (68 min). This has helped the dissemination beyond large metropolitan centres. In addition, due to the low background activity in the urinary bladder (1.2% injected dose over 2 h compared to 10% injected dose over 2 h for 68 Ga), 18 F-PSMA helps detect local recurrence or spread to pelvic nodes more readily as lesions are not masked by physiological urinary excretion. Despite excellent sensitivities of PSMA positron emission tomography modalities, it is noteworthy that PSMA expression is not specific to the prostate. A variety of normal tissues express PSMA with intense uptake noted in salivary glands, lacrimal glands, the liver, spleen, pancreas, small intestine, bladder and renal cortex. In this case report, we describe an example of non-prostatic PSMA uptake in a patient imaged with 18 F-PSMA-1007 positron emission tomography/CT that showed an avid lytic lesion in manubrium. The patient was subsequently proven by biopsy to have myeloma. Our case report illustrates a potential pitfall when imaging patients with 18 F PSMA-1007 and adds to the growing body of literature of non-prostatic uptake of PSMA and highlights the need for reporters to be aware of this uptake.